US › Healthcare

Kiora Pharmaceuticals Inc (KPRX)

US · Healthcare · Biotechnology

$2.67+2.69%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.1M

EPS

$-0.34

EPS estimate

$-0.62

EPS came in at -0.34 against a street estimate of -0.62 — a beat of 45.2%.

Key statistics

Market cap

$11.7M

Forward P/E

2.4

P/B

0.68

Book value

$3.81

EPS (TTM)

$-2.48

52-week high

$2.95

52-week low

$1.76

50-day MA

$2.57

200-day MA

$2.34

Beta

-0.33

Analyst view

Analysts rate Kiora Pharmaceuticals Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $12.00.

Shareholding

Insiders

3.09%

Institutions

36.35%

Largest institutional holders

Fund	Stake
ADAR1 Capital Management LLC	3.79%
Millennium Management LLC	1.68%
Citadel Advisors Llc	1.12%
Geode Capital Management, LLC	1.08%
Vanguard Capital Management, LLC	0.45%
XTX Topco Ltd	0.33%
Vanguard Fiduciary Trust Co	0.29%
Dimensional Fund Advisors, Inc.	0.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kiora Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.